Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MicCAT: Telmisartan in Essential Hypertension
NCT02242370Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 1999
- Primary completion
- Nov 2000
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of telmisartan in essential hypertension (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change in diastolic blood pressure at 6 weeks, Change in systolic blood pressure at 6 weeks and 1 more. Started Sep 1999; status: completed.
02
Drugs
telmisartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02242370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242370.